Product nameAnti-Carboxymethyl Lysine antibody [NF-1G]
See all Carboxymethyl Lysine primary antibodies
DescriptionMouse monoclonal [NF-1G] to Carboxymethyl Lysine
SpecificityThis antibody is suitable for the detection of N Epsilon (Carboxymethyl) Lysine (CML) in tissues and tissue extracts.
Tested applicationsSuitable for: ELISA, IHC-Fr, IHC-Pmore details
Species reactivityReacts with: Species independent
N Epsilon (Carboxymethyl) Lysine (CML)-HSA.
Storage instructionsShipped at 4°C. Upon delivery aliquot and store at -20°C. Avoid freeze / thaw cycles.
Storage bufferPreservative: 0.1% Proclin
Ascites in stabilized buffer, containing 50% Block Ace (Casein-containing solution) and 0.1% ProClin as a preservative.
Concentration information loading...
PurityProtein G purified
- Pathways and Processes
- Metabolic signaling pathways
- Energy transfer pathways
- Energy Metabolism
Our Abpromise guarantee covers the use of ab30917 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
|ELISA||Use a concentration of 0.1 - 0.5 µg/ml.|
|IHC-Fr||Use a concentration of 2 µg/ml.|
|IHC-P||Use at an assay dependent concentration.|
RelevanceN epsilon carboxymethyl lysine (CML or Carboxymethyl Lysine) is formed by the non enzymatic Schiff base reaction of glucose with proteins, followed by an Amadori rearrangement and oxidation that leaves only a carboxymethyl group attached to the lysine. The levels of CML adducts accumulate over time and have been used as an indicator of both serum glucose levels and oxidative protein damage. Elevated serum CML modified proteins have been associated with diabetes and may contribute to diabetic retinopathy, nephropathy and angiopathy.
- CML antibody
- N Epsilon (Carboxymethyl) Lysine antibody
ab30917 staining Carboxymethyl Lysine in Human skin tissue sections by Immunohistochemistry (IHC-P - paraformaldehyde-fixed, paraffin-embedded sections). Tissue was fixed with formalin and embedded in paraffin. Samples were incubated with primary antibody (1/125 in PBS + 1% BSA) for overnight at 4°C. A Biotin-conjugated secondary was used with DAB visualisation the samples were then counterstained with haematoxylin.
This product has been referenced in:
- Zhuang A et al. Increased liver AGEs induce hepatic injury mediated through an OST48 pathway. Sci Rep 7:12292 (2017). IHC . Read more (PubMed: 28947796) »
- Crisan M et al. Expression of Advanced Glycation End-Products on Sun-Exposed and Non-Exposed Cutaneous Sites during the Ageing Process in Humans. PLoS One 8:e75003 (2013). IHC-P ; Human . Read more (PubMed: 24116020) »